BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Jan. 24, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a company focused on the development and commercialization of
novel cardiovascular diagnostics, today announced that it intends to offer and
sell shares of its common stock in an underwritten public offering. BG
Medicine also expects to grant the underwriters a 30-day option to purchase
additional shares of common stock to cover over-allotments, if any. Lazard
Capital Markets LLC is acting as sole book-running manager for the offering.
While the offering is expected to price before 9:30 am EST on January 25,
2013, the offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or as to the
actual size or terms of the offering.

A registration statement on Form S-3 relating to the common stock offered in
this offering was filed with, and declared effective by, the Securities and
Exchange Commission (the "SEC"). A preliminary prospectus supplement, as well
as a final prospectus supplement, relating to and describing the terms of the
offering will be filed with the SEC, each of which will form a part of the
effective registration statement. When available, copies of the preliminary
and final prospectus supplements relating to these securities may be obtained
by visiting the SEC's website at or from Lazard Capital Markets
LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020 or via telephone at
(800) 542-0970.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the securities
laws of any such jurisdiction.

About BG Medicine, Inc.

BG Medicine, Inc. is a diagnostics company focused on the development and
commercialization of novel cardiovascular tests to address significant unmet
medical needs, improve patient outcomes and reduce healthcare costs. The
Company has two products: the BGM Galectin-3® test for use in patients with
chronic heart failure is available in the United States and Europe; and the
CardioSCORE™ test for the risk prediction of major cardiovascular events will
be launched in Europe in the first half of 2013. For additional information
about BG Medicine, heart failure and galectin-3 testing, please visit and

The BG Medicine Inc. logo is available at

Forward-Looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section27A of the Securities Act of 1933, as
amended, and Section21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms. Forward-looking statements in this
news release include, but are not limited to, those regarding BG Medicine's
expectations regarding its fundraising efforts, including its intention to
offer and sell shares of its common stock in an underwritten public offering,
its expectation that it will grant the underwriters an option to purchase
additional shares, and its expectations regarding the timing of the pricing,
the price and the other terms of the offering. Forward-looking statements are
based on management's current expectations and involve inherent risks and
uncertainties which could cause actual results to differ materially from those
in the forward-looking statements, as a result of various factors including
those risks and uncertainties described in the Risk Factors and in
Management's Discussion and Analysis of Financial Condition and Results of
Operations sections of our recent filings with the Securities and Exchange
Commission, including a preliminary prospectus supplement and Current Report
on Form 8-K both filed on January 24, 2013, our most recent Annual Report on
Form 10-K and Quarterly Reports on Form 10-Q. We urge you to consider those
risks and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such forward-looking
statements, which speak only as of the date made. Except as otherwise required
by the federal securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking statement
contained herein (or elsewhere) to reflect any change in our expectations with
regard thereto or any change in events, conditions or circumstances on which
any such statement is based.

CONTACT: Chuck Abdalian
         EVP & Chief Financial Officer
         Tel. (781) 434-0210

BG Medicine Inc. logo
Press spacebar to pause and continue. Press esc to stop.